Prediction of neutrophil nadir and recovery following paediatric haematopoietic cell transplantation with busulfan conditioning.

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Beth Apsel Winger, Joseph W Polli, Janel Long-Boyle, Andrew Weber, Jordan Brooks, Jaimit Parikh, Valeriu Damian
{"title":"Prediction of neutrophil nadir and recovery following paediatric haematopoietic cell transplantation with busulfan conditioning.","authors":"Beth Apsel Winger, Joseph W Polli, Janel Long-Boyle, Andrew Weber, Jordan Brooks, Jaimit Parikh, Valeriu Damian","doi":"10.1002/bcp.70251","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>In haematopoietic cell transplantation (HCT), neutropenia resulting from myelosuppression is an expected endpoint following busulfan-based conditioning. However, if prolonged, neutropenia can lead to complications like serious infection and death. The routine use of pharmacokinetic (PK)-guided busulfan dosing has decreased toxicities; however, patients still have serious, sometimes fatal, complications of drug-induced neutropenia. We sought to investigate whether the time-course of neutropenia after HCT could be predicted for paediatric patients following busulfan-based conditioning. Such predictions could guide care, such as timing of infectious prophylaxis and/or growth factor administration.</p><p><strong>Methods: </strong>This was a single-centre, retrospective study of 146 patients with malignant or nonmalignant disorders treated with allogeneic or autologous HCT. An advanced PKPD model of neutrophil dynamics post-HCT was built that included two parallel neutrophil maturation pathways for host and donor cells, expanded transit compartments for neutrophil maturation, cell number-based feedback loops to the proliferating compartment, GCSF effects, and direct/indirect busulfan killing effects.</p><p><strong>Results: </strong>The model predicted neutrophil recovery well using patient data beyond Day +21 post-HCT. When using patient data prior to Day +21 post-HCT, neutrophil recovery was less accurate (as measured by the sum of the absolute neutrophil count prediction error) due to unpredictable complications influencing neutrophil counts. Four clinical cases illustrate the strengths and challenges of the model.</p><p><strong>Conclusions: </strong>This study suggests real-time incorporation of patient-specific data through Day +21 post-HCT is required to predict neutrophil dynamics following neutrophil nadir in paediatric HCT.</p>","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/bcp.70251","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: In haematopoietic cell transplantation (HCT), neutropenia resulting from myelosuppression is an expected endpoint following busulfan-based conditioning. However, if prolonged, neutropenia can lead to complications like serious infection and death. The routine use of pharmacokinetic (PK)-guided busulfan dosing has decreased toxicities; however, patients still have serious, sometimes fatal, complications of drug-induced neutropenia. We sought to investigate whether the time-course of neutropenia after HCT could be predicted for paediatric patients following busulfan-based conditioning. Such predictions could guide care, such as timing of infectious prophylaxis and/or growth factor administration.

Methods: This was a single-centre, retrospective study of 146 patients with malignant or nonmalignant disorders treated with allogeneic or autologous HCT. An advanced PKPD model of neutrophil dynamics post-HCT was built that included two parallel neutrophil maturation pathways for host and donor cells, expanded transit compartments for neutrophil maturation, cell number-based feedback loops to the proliferating compartment, GCSF effects, and direct/indirect busulfan killing effects.

Results: The model predicted neutrophil recovery well using patient data beyond Day +21 post-HCT. When using patient data prior to Day +21 post-HCT, neutrophil recovery was less accurate (as measured by the sum of the absolute neutrophil count prediction error) due to unpredictable complications influencing neutrophil counts. Four clinical cases illustrate the strengths and challenges of the model.

Conclusions: This study suggests real-time incorporation of patient-specific data through Day +21 post-HCT is required to predict neutrophil dynamics following neutrophil nadir in paediatric HCT.

预测中性粒细胞最低点和恢复后的儿科造血细胞移植与布苏凡调理。
目的:在造血细胞移植(HCT)中,骨髓抑制导致的中性粒细胞减少是布苏凡基础调理后的预期终点。然而,如果时间延长,中性粒细胞减少症会导致严重感染和死亡等并发症。常规使用药代动力学(PK)引导的丁硫丹剂量降低了毒性;然而,患者仍然有严重的,有时是致命的药物性中性粒细胞减少症并发症。我们试图调查是否可以预测儿童患者在接受布苏凡治疗后HCT后中性粒细胞减少的时间过程。这样的预测可以指导护理,例如传染病预防和/或生长因子管理的时机。方法:这是一项单中心、回顾性研究,146例恶性或非恶性疾病患者接受同种异体或自体HCT治疗。建立了hct后中性粒细胞动力学的先进PKPD模型,包括宿主和供体细胞的两条平行中性粒细胞成熟途径,扩大中性粒细胞成熟的转运室,基于细胞数量的增殖室反馈回路,GCSF效应和直接/间接的busulfan杀伤效应。结果:该模型使用hct后第21天以上的患者数据很好地预测了中性粒细胞恢复。当使用hct后第21天之前的患者数据时,由于不可预测的并发症影响中性粒细胞计数,中性粒细胞恢复的准确性较低(通过绝对中性粒细胞计数预测误差的总和来测量)。四个临床案例说明了该模型的优势和挑战。结论:本研究表明,需要通过HCT后第21天实时合并患者特异性数据来预测小儿HCT中性粒细胞最低点后的中性粒细胞动态。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
8.80%
发文量
419
审稿时长
1 months
期刊介绍: Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信